Clinical effects of growth hormone on bone: a review

References

• Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH on bone metabo- lism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol 1998;48:561–8
   PubMed Web of Science ®Google Scholar
• Ohlsson C, Bengtsson BA, Isaksson OG, An- dreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev 1998;10:55–79
   Google Scholar
• Amato G, Carella C, Fazio S, et al. Body composition, body metabolism and heart structure and function in growth hormone (GH)-deficient adults before and after GH replacement therapy at low doses. J Clin Endocrinol Metab 1993;77:1671–6
   PubMed Web of Science ®Google Scholar
• Amato G, Izzo G, La Montagna G, Bellastella A. Low dose recombinant human growth hormone normalizes bone metabolism and cortical bone density and improves trabecular bone density in growth hormone deficient adults without causing adverse effects. Clin Endocrinol 1996;45:27–32
   PubMedGoogle Scholar
• Sartorio A, Conti, A, Monzani M. New markers of bone and collagen turnover in children and adults with growth hormone deficiency. Postgrad- uate Med J 1993;69:846–50
   PubMed Web of Science ®Google Scholar
• Bing-You RG, Denis MC, Rosen CJ. Low bone mineral density in adults with previous hypotha- lamic-pituitary tumors: correlations with serum growth hormone response to GH-releasing hor- mone, insulin-like growth factor I, and IGF binding protein 3. Calcif Tissue Int 1993;52:183–7
   PubMedGoogle Scholar
• De Boer H, Blok GJ, van Lingen, A, Teule GJ, Lips P, van der Veen EA. Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res 1994;9:1319– 26
   Google Scholar
• Elgindy N, Grunditz, R, Thoren M, Degerblad M, Sjo¨ berg HE, Ringertz H. Longterm follow-up of metacarpal cortical thickness and bone mineral density in panhypopituitarism. Radiol Diag 1991; 32:326–30
   Google Scholar
• Holmes SJ, Economou G, Whitehouse RW, Adams JE, Shalet SM. Reduced bone mineral density in patients with adult-onset growth hormone deficiency. J Clin Endocrinol Metab 1994;78:669–74
   PubMed Web of Science ®Google Scholar
• Kann P, Piepkorn B, Schehler B, et al. Replace- ment therapy with recombinant human growth hormone (GH) in GH-deficient adults: effects on bone metabolism and bone mineral density in a 2- year prospective study. Endocrinol Metab 1995; 2:103–10
   Google Scholar
• Kaufman JM, Taelman P, Vermeulen A, Vande- weghe M. Bone mineral status in growth hormone deficient males with isolated and multi- ple pituitary deficiencies of childhood onset. J Clin Endocrinol Metab 1992;74:118–23
   PubMed Web of Science ®Google Scholar
• Rosen T, Hansson T, Granhed H, Szucs J, Bengtsson B-A. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinol 1993;129:201–6
   PubMedGoogle Scholar
• Rosen T, Wilhelmsen L, Landin-Wilhelmsen K, et al. Increased fracture rate in adults with growth hormone deficiency. Endocrinol Metab 1996;3:121
   Google Scholar
• Wuster C, Slenczka E, Ziegler R. Increased prevalence of osteoporosis and arteriosclerosis in conventionally substituted anterior pituitary in- sufficiency: need for additional growth hormone substitution? Klin Wochenschr 1991;69:769–73
   PubMedGoogle Scholar
• Wuster C, Abs R, Bengtsson BA, et al. for KIMS Study Group and the KIMS International Board. Pharmacia & Upjohn International Metabolic Database. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res 2001;16:398–405
   PubMed Web of Science ®Google Scholar
• Ahmad AM, Thomas J, Clewes A, et al. Effects of growth hormone replacement on parathyroid hormone sensitivity and bone mineral metabo- lism. J Clin Endocrinol Metab 2003;88:2860–8
   PubMed Web of Science ®Google Scholar
• Balducci R, Toscano V, Pasquino AM, et al. Bone turnover and bone mineral density in young adult patients with panhypopituitarism before and after long-term growth hormone therapy. Eur J Endocrinol 1995;132:42–6
   PubMedGoogle Scholar
• Beshyah SA, Thomas E, Kyd P, Sharp P, Fairney A, Johnston DG. The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism. Clin Endocrinol 1994;40:383–91
   PubMed Web of Science ®Google Scholar
• Beshyah SA, Kyd P, Thomas E, Fairney A, Johnston DG. The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults. Clin Endocrinol 1995;42:249–54
   PubMedGoogle Scholar
• Degerblad M, Elgindy N, Hall K, Sjo¨ berg H-E, Thoren M. Potent effect of recombinant growth hormone on bone mineral density and body composition in adults with panhypopituitarism. Acta Endocrinol 1992;126:387–93
   PubMedGoogle Scholar
• Hansen TB, Brixen K, Vahl N, et al. Effects of 12 months of growth hormone (GH) treatment on calciotropic hormones, calcium homeostasis, and bone metabolism in adults with acquired GH deficiency: a double blind, randomized, placebo- controlled study. J Clin Endocrinol Metab 1996;81:3352–9
   PubMedGoogle Scholar
• Vandeweghe M, Taelman P, Kaufman JM. Short and long-term effects of growth hormone treat- ment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clin Endocrinol 1993;39:409–15
   PubMedGoogle Scholar
• Ernst M, Froesch ER. Growth hormone depen- dent stimulation of osteoblast-like cells in serum- free cultures via local synthesis of insulin-like growth factor I. Biochem Biophys Res Commun 1988;151:142–7
   PubMed Web of Science ®Google Scholar
• Maor G, Hochberg Z, Von der Murk K, Heinegard D, Silberman MM. Human growth hormone enhances chondrogenesis and osteo- genesis in a tissue culture system of chondro- progenitor cells. Endocrinology 1992;125:1239–45
   Google Scholar
• Nishiyama K, Sugimoto T, Kaji H, Kanatani M, Kobayashi T, Chihara K. Stimulatory effect of growth hormone on bone resorption and osteo- clast differentiation. Endocrinology 1996;137:35–41
   PubMed Web of Science ®Google Scholar
• Slootweg MC, van Buul-Offers SC, Herrmann- Erlec MPM, van der Meer JM, Duursma SA. Growth hormone is mitogenic for fetal mouse osteoblasts but not for undifferentiated bone cells. J Endocrinol 1988;116:R11–13
   Web of Science ®Google Scholar
• Stracke H, Schulz A, Moeller D, Rossol S, Schatz H. Effect of growth hormone on osteoblasts and demonstration of somatomedin-C IGF-1 in bone organ culture. Acta Endocrinol 1984;107:16–24
   PubMedGoogle Scholar
• Abrahamsen B, Hangaard J, Horn HC, et al. Evaluation of the optimum dose of growth hormone (GH) for restoring bone mass in adult- onset GH deficiency: results from two 12-month randomized studies. Clin Endocrinol 2002;57:273–81
   PubMedGoogle Scholar
• Baum HB, Biller BM, Finkelstein JS, et al. Effects of physiologic growth hormone therapy on bone density and body composition in patients with adult-onset growth hormone deficiency. A ran- domized, placebo-controlled trial. Ann Intern Med 1996;125:883–90
   PubMed Web of Science ®Google Scholar
• Bex M, Abs R, Maiter D, Beckers A, Lamberigts G, Bouillon R. The effects of growth hormone replacement therapy on bone metabolism in adult-onset growth hormone deficiency: a 2-year open randomized controlled multicenter trial. J Bone Miner Res 2002;17:1081–94
   PubMed Web of Science ®Google Scholar
• Degerblad M, Bengtsson BA, Bramnert M, et al. Reduced bone mineral density in adults with growth hormone (GH) deficiency: increased bone turnover during 12 months of GH substitution therapy. Eur J Endocrinol 1995;133:180–8
   PubMedGoogle Scholar
• Finkenstedt G, Gasser RW, Hofle G, Watfah C, Fridrich L. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up. Eur J Endocrinol 1997;136:282–9
   PubMedGoogle Scholar
• Gomez JM, Gomez N, Fiter J, Soler J. Effects of long-term treatment with GH in the bone mineral density of adults with hypopituitarism and GH deficiency and after discontinuation of GH replacement. Horm Metab Res 2000;32:66–70
   PubMedGoogle Scholar
• Holmes SJ, Whitehouse RW, Swindell R, Economou G, Adams JE, Shalet SM. Effect of growth hormone replacement on bone mass in adults with adult onset growth hormone defi- ciency. Clin Endocrinol 1995;42:627–33
   PubMed Web of Science ®Google Scholar
• Sneppen SB, Hoeck HC, Kollerup G, Sorensen OH, Laurberg P, Feldt-Rasmussen U. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults – an 18-month randomised, placebo- controlled, double blinded trial. Eur J Endocrinol 2002;146:187–95
   PubMedGoogle Scholar
• Johannsson G, Rosen T, Bosacus I, Sjo¨ stro¨m L, Bengtsson B-A. Two years growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult- onset GH deficiency. J Clin Endocrinol Metab 1996; 81:2865–73
   PubMed Web of Science ®Google Scholar
• Baroncelli GI, Bertelloni S, Sodini F, Saggese G. Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumber BMD. Clin Endocrinol 2004;60:175–84
   PubMedGoogle Scholar
• Shalet SM, Shavrikova E, Cromer M, et al. Effect of growth Hormone (GH) treatment on bone in postpubertal GH-deficient patients: a 2-year randomized, controlled, dose-ranging study. J Clin Endocrinol Metab 2003;88:4124–9
   PubMed Web of Science ®Google Scholar
• Dennison EM, Hindmarsh PC, Kellingray S, Fall CH, Cooper C. Growth hormone predicts bone density in elderly women. Bone 2003;32:434–40
   PubMedGoogle Scholar
• Rico H, Del-Rio A, Vila T, Patino R, Carrera F, Espinos D. The role of growth hormone in the pathogenesis of postmenopausal osteoporosis. Arch Intern Med 1979;139:1263–5
   PubMedGoogle Scholar
• Dequeker J, Burssens A, Boullion R. Dynamics of growth hormone secretion in patients with osteoporosis and in patients with osteoarthrosis. Horm Res 1982;16:353–6
   PubMedGoogle Scholar
• Li G, Zeng M. Relation of serum growth hormone and estradiol levels and osteoporosis in postmenopausal women. Chung Hua Tsa Chin Taipei 1990;70:16–19
   Google Scholar
• Rubin CD. Southwestern internal medicine conference: growth hormone – aging and osteo- porosis. Am J Med Sci 1993;305:120–9
   Google Scholar
• Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen EF. No evidence for reduced sponta- neous or growth hormone stimulated serum levels of insulin-like growth factor (IGF)-1, IGP-II or IGF binding protein 3 in women with spinal osteoporosis. Eur J Endocrinol 1994;131:150–5
   PubMedGoogle Scholar
• Johansson AG, Eriksen EF, Lindh E, et al. Reduced serum levels of the growth hormone- dependent insulin-like growth factor binding protein and a negative bone balance at the level of individual remodeling units in idiopathic osteoporosis in men. J Clin Endocrinol Metab 1997;82:2795–8
   PubMedGoogle Scholar
• Kurland BS, Chan PK, Rosen CJ, Bilezikian JP. Normal growth hormone secretory reserve in men with idiopathic osteoporosis and reduced circulating levels of insulin-like growth factor-I. J Clin Endocrinol Metab 1998;83:2576–9
   PubMedGoogle Scholar
• Gillberg P, Johansson AG, Blum WF, Groth T, Ljunghall S. Growth hormone secretion and sensitivity in men with idiopathic osteoporosis. Calcif Tissue Int 2001;68:67–73
   PubMedGoogle Scholar
• Kruse HP, Kuhlencordt F. On an attempt to treat primary and secondary osteoporosis with human growth hormone. Horm Metab Res 1975;7:488–91
   PubMedGoogle Scholar
• Aloia JF, Zanzi I, Ellis K, et al. Effects of growth hormone in osteoporosis. J Clin Endocrinol Metab 1976;43:992–9
   PubMedGoogle Scholar
• Aloia JF, Vaswani A, Kapoor A, Yeh JK, Cohn SH. Treatment of osteoporosis with calcitonin, with and without growth hormone. Metabolism 1985;34:124–9
   PubMedGoogle Scholar
• Aloia JF, Vaswani A, Meunier PJ, et al. Coherence treatment of postmenopausal osteo- porosis with growth hormone and calcitonin. Calcif Tissue Int 1987;40:253–9
   PubMedGoogle Scholar
• Brixen K, Kassem M, Eriksen EF, Nielsen HK, Flyvbjerg A, Mosekilde L. Growth hormone (GH) and adult bone remodelling: the potential use of GH in treatment of osteoporosis. J Pediatr Endocrinol 1993;6:65–71
   PubMedGoogle Scholar
• Eriksen EF, Kassem M. Brixen K. Growth hormone and insulin-like growth factors as anabolic therapies for osteoporosis. Horm Res 1993;40:95–8
   PubMedGoogle Scholar
• Kassem M, Brixen K, Mosekilde I, Eriksen EF. Human marrow stromal osteoblast-like cells do not show reduced responsiveness to in vitro stimulation with growth hormone in patients with postmenopausal osteoporosis. Calcif Tissue Int 1994;54:1–6
   PubMedGoogle Scholar
• Kassem M, Brixen K, Blum W, Mosekilde I, Eriksen EF. Normal osteoclastic and osteoblastic response to exogenous growth hormone in patients with postmenopausal spinal osteoporosis. J Bone Miner Res 1994;9:1365–70
   PubMedGoogle Scholar
• Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K. Effect of recombinant human growth hormone in elderly osteoporotic women. Clin Endocrinol 1999; 51:715–24
   PubMedGoogle Scholar
• Sugimoto T, Kaji H, Nakaoka D, et al. Effect of low-dose of recombinant human growth hor- mone on bone metabolism in elderly women with osteoporosis. Eur J Endocrinol 2002;147:339–48
   PubMedGoogle Scholar
• Saaf M, Hilding A, Thoren M, Troell S, Hall K. Growth hormone treatment of osteoporotic postmenopausal women – a one year placebo- controlled study. Eur J Endocrinol 1999;140:390–9
   PubMedGoogle Scholar
• Erdtsieck RJ, Pols, HA, Valk NK, et al. Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidro- nate: a placebo controlled trial. Clin Endocrinol 1995;43:557–65
   PubMed Web of Science ®Google Scholar
• Gonnelli S, Cepollaro C, Montomoli M, et al. Treatment of postmenopausal osteoporosis with recombinant human growth hormone and salmon calcitonin: a placebo controlled study. Clin Endocrinol 1997;46:55–61
   PubMedGoogle Scholar
• Johansson AG, Lindh E, Blum WF, Kollerup G, Sorensen OH, Ljunghall SJ. Effects of growth hormone and insulin-like growth factor I in men with idiopathic osteoporosis. J Clin Endocrinol Metab 1996;81:44–8
   PubMed Web of Science ®Google Scholar
• Gillberg P, Mallmin H, Petren-Mallmin M, Ljunghall S, Nilsson AG. Two years of treatment with recombinant human growth hormone in- creases bone mineral density in men with idiopathic osteoporosis. J Clin Endocrinol Metab 2002;87:4900–6
   PubMed Web of Science ®Google Scholar
• Papanicolaou DA, Wilder RL, Manolagos SC, Chrousos GP. The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 1998;128:127–37
   PubMed Web of Science ®Google Scholar
• Franco P, Marelli O, Lattuada D, Locatelli V, Cocchi D, Muller EE. Influence of growth hormone on the immunosuppressive effect of prednisolone in mice. Acta Endocrinol Copenh 1990;123:339–44
   PubMedGoogle Scholar
• Ortoft G, Oxlund H. Qualitative alterations of cortical bone in female rats after long-term administration of growth hormone and glucocor- ticoid. Bone 1996;18:581–90
   PubMedGoogle Scholar
• Swolin-Eide D, Nilsson A, Ohlsson C. Cortisol increases growth hormone-receptor expression in human osteoblast-like cells. J Endocrinol 1998; 156:99–105
   PubMedGoogle Scholar
• Giustina A, Bussi AR, Jacobello C, Wehrenberg WB. Effects of recombinant growth hormone (GH) on bone and intermediary metabolism in patients receiving chronic glucorticoid treatment with suppressed endogenous GH response to GH-releasing hormone. J Clin Endocrinol Metab 1995;80:122–9
   PubMedGoogle Scholar
• Ott SM, Aitken ML. Osteoporosis in patients with cystic fibrosis. Clin Chest Med 1998;19:555–67
   PubMedGoogle Scholar
• Tanaka H, Seino Y. Does growth hormone treatment prevent corticosteroid-induced osteo- porosis? Bone 1996;18:493–4
   PubMedGoogle Scholar
• Brill KT, Weltman AL, Gentili A, et al. Single and combined effects of growth hormone and testosterone administration on measures of body composition, physical performance, mood, sexual function, bone turnover, and muscle gene expres- sion in healthy older men. J Clin Endocrinol Metab 2002;87:5649–57
   PubMed Web of Science ®Google Scholar
• Rudman D, Feller AG, Nagraj HS, et al. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990;323:1–6
   PubMed Web of Science ®Google Scholar
• Renehan AG, O’Connell J, O’Halloran D, et al. Acromegaly and colorectal cancer: a comprehen- sive review of epidemiology, biological mechanisms, and clinical implications. Horm Metab Res 2003;35:712–25
   PubMed Web of Science ®Google Scholar
• Mucci LA, Tamimi R, Lagiou P, et al. Are dietary influences on the risk of prostate cancer mediated through the insulin-like growth factor system? BJU Int 2001;87:814–20
   PubMed Web of Science ®Google Scholar
• Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000;18:847–53
   PubMed Web of Science ®Google Scholar
• Giovannucci E, Pollak M, Platz EA, et al. Insulin- like growth factor I (IGF-I), IGF-binding protein- 3 and the risk of colorectal adenoma and cancer in the Nurses’ Health Study. Growth Horm IGF Res 2000;10SupplA:S30–31
   Google Scholar